Exploring New Schiff Bases: Synthesis, Characterization, and Multifaceted Analysis for Biomedical Applications

• Published in: ACS omega Vol. 9; no. 33; pp. 35431 - 35448
• Main Authors: Thakor, Priteshkumar M., Patel, Jatin D., Patel, Rajesh J., Chaki, Sunil H., Khimani, Ankurkumar J., Vaidya, Yati H., Chauhan, Anita P., Dholakia, Amit B., Patel, Vishant C., Patel, Ankitkumar J., Bhavsar, Nirav H., Patel, Hiteshkumar V.
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 20.08.2024
• ISSN: 2470-1343; 2470-1343
• DOI: 10.1021/acsomega.4c02007

The current work aims to generate novel Schiff bases by reacting substituted aldehydes with amine derivatives catalyzed by a natural acid. The developed compounds underwent diverse physicochemical analyses including liquid chromatography–mass spectrometry, Fourier transform infrared spectroscopy, scanning electron microscopy, 1H- and 13C-nuclear magnetic resonance, and X-ray diffraction. Furthermore, differential thermogravimetric, thermogravimetric, and differential thermal analysis techniques were employed in a nitrogen-free environment to determine kinetic parameters. These data were then used in model-free isoconversional methods (e.g., Friedman, Kissinger–Akahira–Sunose, and Flynn–Wall–Ozawa). The Schiff bases were evaluated for their in vitro and in silico α-amylase inhibitory activity. Schiff base-2 displayed the highest inhibition compared with the reference drug acarbose. In comprehensive MTT assay cytotoxicity investigations, both Schiff bases showed strong anticancer capabilities against the human lung cancer cell line (A549). Moreover, this study demonstrated effectiveness of synthetic compounds in screening Caenorhabditis elegans for anti-Alzheimer’s and stress resistance properties. The simplicity of its biology allowed precise evaluation of the effect of compounds on neuronal function and stress response. This research enhances drug discovery efforts for Alzheimer’s and stress-related disorders, potentially improving patient outcomes.